- 2014
-
Press releases - 26.11.2014
Anne Dejean-Assémat, is awarded the Inserm Grand Prix for 2014
The Inserm Grand Prix is awarded to Anne Dejean-Assémat, director of Inserm/Institut Pasteur Joint Unit 993 “Nuclear Organization and Oncogenesis,” for her entire body of research on the molecular and cellular mechanisms involved in the development of human cancers.
-
Press releases - 24.11.2014
Stroke (CVA) in young adults: discovery of a susceptibility gene associated with bleeding of the cervical arteries
Researchers from the joint research unit “Public health and molecular epidemiology of aging related diseases” (Inserm/Institut Pasteur Lille/Université Lille 2), in collaboration with Lille Regional University Hospital (CHRU), have discovered a susceptibility gene involved in this major cause of stroke (cerebrovascular accident) in young subjects.
-
Press releases - 20.11.2014
Pirate viruses caught in their own trap ?
A group of scientists in Strasbourg has demonstrated that one of the 80 components of each ribosome is essential for infection by certain viruses without being necessary for normal cell functioning.
-
Press releases - 19.11.2014
Launch of GrippeNet.fr 2014-2015 season
Launched 3 years ago by the Sentinelles Network (Inserm–Pierre and Marie Curie University Joint Research Unit 1136) and the French Institute for Public Health Surveillance (InVS), the GrippeNet.fr website returns for a fourth consecutive year.
-
Press releases - 17.11.2014
A better understanding of accidents in everyday life
During their lives, every French person will be the victim of one accident in everyday life every 5 years, on average (fall, burn, drowning, etc.). Taken as a whole, these statistics represent 11 million people injured every year. The Accident Prevention and Trauma Treatment team led by Emmanuel Lagarde (Inserm Unit 897), in partnership with Calyxis, is today launching the MAVIE study to find out the scale and nature of accidents in everyday life in France.
-
Press releases - 14.11.2014
Avoiding skin graft rejection: it’s possible!
A research team bringing together José Cohen and Philippe Grimbert (Inserm Unit 955/Université Paris Est Créteil [UPEC] and the Centre for Clinical Investigation – Biotherapies 504 [CIC-BT 504]), and their collaborators at Institut Curie and AP-HP (George Pompidou European Hospital) has succeeded in finding a combination of drugs that reduces the risk of rejection following a skin graft. When tested in mice, this treatment seems effective, since no sign of rejection is observed nearly 30 days after transplantation.
-
Press releases - 13.11.2014
MSF and Inserm join their forces against Ebola : first trials
In the absence of specific treatments for Ebola, international medical humanitarian organisation Médecins Sans Frontières/Doctors Without Borders (MSF) announced today that it will host clinical trials in three Ebola treatment centres in West Africa.
-
What's on? - 13.11.2014
MSF and Inserm join their forces against Ebola : first trials
In the absence of specific treatments for Ebola, international medical humanitarian organisation Médecins Sans Frontières/Doctors Without Borders (MSF) announced today that it will host clinical trials in three Ebola treatment centres in West Africa. The separate trials, which are aimed at quickly finding an effective therapy that can be used against the disease which has […]
-
Press releases - 12.11.2014
November 14th 2014: World Diabetes Day
Initiated in 1991 by the International Diabetes Federation and World Health Organization, World Diabetes Day is aimed at making the general public aware and informed about prevention and management.
-
What's on? - 12.11.2014
November 14th 2014: World Diabetes Day
Diabetes type 1 or type 2 is a chronic disease caused by an insufficient mass of pancreatic beta cells, which produce insulin, or by poor use of this hormone by the body. This results in an elevated level of glucose in the bloodstream (hyperglycaemia), and may lead to serious complications (infarct, impaired vision, blindness, stroke, […]